ECM
MDGL icon

Everence Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Everence Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Buy
558
+18
+3% +$9.22K 0.02% 631
2026
Q1 		$283K Hold
540
– – 0.02% 596
2025
Q4 		$314K Hold
540
– – 0.02% 565
2025
Q3 		$248K Buy
+540
New +$201K 0.01% 685

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Everence Capital Management's MDGL Position: Q2 2026 in Review

Everence Capital Management increased its Madrigal Pharmaceuticals (MDGL) stake by 3.3% in Q2 2026, buying an estimated $9.22K and bringing the position to 558 shares worth $300K. The position accounts for 0.02% of the portfolio, ranked #631.

Everence Capital Management first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. The position peaked at $314K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Everence Capital Management held 558 shares of Madrigal Pharmaceuticals worth $300K as of Q2 2026.
  • Everence Capital Management bought 18 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $9.22K.
  • Madrigal Pharmaceuticals made up 0.02% of Everence Capital Management's portfolio in Q2 2026, its #631 holding.
  • Everence Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Everence Capital Management's Madrigal Pharmaceuticals position peaked at $314K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.